Infusion Nursing Notes by Nufactor provides education, resources and support to promote successful patient therapy within the infusion nursing community.

HYQVIA® 10% — Learn About Expanded FDA-Approval for Treating PIDD and CIDP

23. May 2025 Marianna Herrera Nursing Support (0)
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration was first FDA-approved in 2014 for primary immunodeficiency (PIDD) in adults. In 2023, HYQVIA® received expanded FDA-approval in PIDD to include pediatric patients aged 2-16. In 2024 HYQVIA® received FDA-approval for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). [More]

Payers

IG & Coagulation Resources
Site of Care Savings

Support

Contact Us
Refer a Patient
Become a Patient

About Us

Mission & Vision
Core Values
Careers

Nufactor

Service Model
Accreditation
IgCP, IgCN, CSP

Nufactor, Inc. is the specialty pharmacy subsidiary of FFF Enterprises.

Nufactor Corporate
Headquarters
44900 Winchester Road
Temecula, CA 92590

(800) 323-6832

Home • Terms • Privacy Statement • • About Us • Careers
©2022 Nufactor